MedTrace Logo

PTX-35 in Patients With Advanced Solid Tumors

NCT04430348 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-03-12

Study results available
· View outcomes & findings →

Summary

A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

PTX-35

Monoclonal antibody PTX-35

Sponsors & Collaborators

  • Pelican Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Anthony W Tolcher, MD · Next Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-04
Primary Completion
2022-11-02
Completion
2023-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04430348 on ClinicalTrials.gov